



## Original Reports

## Widespread Pressure Delivered by a Weighted Blanket Reduces Chronic Pain: A Randomized Controlled Trial

Jennifer N. Baumgartner, Desiree Quintana, Linda Leija, Nathaniel M. Schuster, Kelly A. Bruno, Joel P. Castellanos, and Laura K. Case

Department of Anesthesiology, University of California San Diego Health, La Jolla, California

**Abstract:** Pleasant sensation is an underexplored avenue for modulation of chronic pain. Deeper pressure is perceived as pleasant and calming, and can improve sleep. Although pressure can reduce acute pain, its effect on chronic pain is poorly characterized. The current remote, double-blind, randomized controlled trial tested the hypothesis that wearing a heavy weighted blanket – providing widespread pressure to the body – relative to a light weighted blanket would reduce ratings of chronic pain, mediated by improvements in anxiety and sleep. Ninety-four adults with chronic pain were randomized to wear a 15-lb. (heavy) or 5-lb. (light) weighted blanket during a brief trial and overnight for one week. Measures of anxiety and chronic pain were collected pre- and post-intervention, and ratings of pain intensity, anxiety, and sleep were collected daily. After controlling for expectations and trait anxiety, the heavy weighted blanket produced significantly greater reductions in broad perceptions of chronic pain than the light weighted blanket (Cohen's  $f = .19$ ,  $CI [-1.97, -.91]$ ). This effect was stronger in individuals with high trait anxiety ( $P = .02$ ). However, weighted blankets did not alter pain intensity ratings. Pain reductions were not mediated by anxiety or sleep. Given that the heavy weighted blanket was associated with greater modulation of affective versus sensory aspects of chronic pain, we propose that the observed reductions are due to interoceptive and social/affective effects of deeper pressure. Overall, we demonstrate that widespread pressure from a weighted blanket can reduce the severity of chronic pain, offering an accessible, home-based tool for chronic pain.

The study purpose, targeted condition, study design, and primary and secondary outcomes were pre-registered in ClinicalTrials.gov (NCT04447885: "Weighted Blankets and Chronic Pain").

**Perspective:** This randomized-controlled trial showed that a 15-lb weighted blanket produced significantly greater reductions in broad perceptions of chronic pain relative to a 5-lb weighted blanket, particularly in highly anxious individuals. These findings are relevant to patients and providers seeking home-based, nondrug therapies for chronic pain relief.

© 2021 by United States Association for the Study of Pain, Inc.

**Key words:** Chronic pain, pressure, anxiety, weighted blanket, pleasant touch, massage.

## Introduction

Chronic pain is the leading cause of disability worldwide.<sup>73</sup> Efforts at treatment have spawned an ongoing

opioid crisis, exposing the need for nondrug treatment options.<sup>113</sup> Chronic pain is amenable to modulation by cognitive interventions such as cognitive behavioral therapy and mindfulness meditation.<sup>107,112,146,162</sup> However, such therapies require resources and training, highlighting a need for more accessible complementary approaches.

Chronic pain has a strong affective component<sup>17</sup> and is frequently accompanied by deficits in emotional regulation.<sup>141</sup> One underexplored therapeutic avenue for modulating chronic pain is pleasant sensation, which shares overlapping affective neural circuitry with pain.<sup>129</sup> By attending to pleasant

Received April 21, 2021; Revised July 8, 2021; Accepted July 22, 2021.

This work was supported by UC San Diego Health and the National Center for Complementary and Integrative Health – National Institutes of Health (R00-AT009466, F32- AT010843).

The authors have no conflicts of interest to disclose.

Address reprint requests to Laura K. Case, PhD, Department of Anesthesiology, University of California San Diego, La Jolla, California. E-mail: [lcas@health.ucsd.edu](mailto:lcas@health.ucsd.edu)

1526-5900/\$36.00

© 2021 by United States Association for the Study of Pain, Inc.

<https://doi.org/10.1016/j.jpain.2021.07.009>

## 2 The Journal of Pain

sensations, individuals may break habitual loops of catastrophizing and negative bias towards incoming sensation that contribute to pain chronification.<sup>60</sup>

The “Social Touch Hypothesis”,<sup>108, 116</sup> more recently referred to as the “Affective Touch Hypothesis”,<sup>98</sup> proposes that the C-tactile (CT) afferent pathway is a specific sensory pathway that conveys the positively valenced social and/or affective components of touch. CT sensory afferents are unmyelinated, low-threshold mechanosensory afferents present predominantly in hairy skin<sup>108,150,161</sup> that respond maximally to gentle stroking at slow velocities (ie, strongest firing for 1-10 cm/s). CT-optimal touch induces positive affect, decreases anxiety,<sup>20,91,92,116,119,120</sup> and activates affective and interoceptive brain regions<sup>20,63,82,97,117</sup> critically involved in descending pain modulation<sup>137</sup> and pain relief by complementary therapies.<sup>153,167,168</sup>

We recently called for the expansion of the Social and/or Affective Touch Hypothesis to include deep pressure<sup>20</sup> – embedded in hugs, cuddling, and massage – as another bottom-up pathway for social and/or affective touch. Deep pressure is employed in therapeutic settings to induce calm<sup>23,64,143</sup> and may be especially beneficial in anxious individuals.<sup>39,64</sup> We recently demonstrated in healthy adults that deep pressure from a compression sleeve is perceived as pleasant and calming, and activates the mid-insula.<sup>20</sup>

Several studies demonstrate that pleasant social and/or affective touch can modulate pain. CT-optimal touch reduces experimental pain in healthy adults<sup>45,67,89,94,111</sup> beyond cognitive effects,<sup>89</sup> and can reduce ratings of chronic pain.<sup>34</sup> Pressure delivered through massage improves mood and pain,<sup>46,49-53,71</sup> with deeper pressure eliciting greater improvements and greater pleasantness.<sup>36,47,58</sup> Widespread mechanical compression also reduces experimental pain in healthy adults,<sup>72</sup> potentially via sensory gating effects.<sup>99,149,160</sup> However, the affective and sensory effects of deep pressure have not been tested in chronic pain.

One potential therapeutic tool to administer deep pressure is a weighted blanket – a blanket sewn with weighted materials that provide widespread pressure to the body. Weighted blankets elicit similar affective effects as deep pressure including feelings of calm<sup>24,41,65</sup> and reductions in anxiety<sup>22,110</sup>. In addition, weighted blankets improve insomnia in healthy adults<sup>2</sup> and psychiatric patients<sup>41</sup>. In addition to sensory gating and modulation of affect,<sup>4,76,122,127,151</sup> weighted blankets could plausibly reduce pain by decreasing anxiety<sup>4,76,122,127,151</sup> or improving sleep.<sup>140,156</sup> The present study tested the hypothesis that a heavy versus light weighted blanket would reduce perceptions of chronic pain, mediated by improvements in anxiety and sleep. Further, we explored whether trait anxiety would alter these effects.

## Method

The current study was a double-blind, between-subjects randomized controlled trial conducted remotely

An RCT of weighted blankets for chronic pain during the COVID-19 pandemic (June to November 2020). A heterogeneous sample of adults with chronic pain were randomly assigned to wear a heavy or light (placebo control) weighted blanket during a brief and weeklong trial, respectively, with self-report and ecological momentary assessment data collected pre-post blanket wearing.

## Participants

The UC San Diego IRB approved procedures in the current study in accordance with the Declaration of the World Medical Association. All participants provided informed consent digitally via Research Electronic Data Capture (REDCap) software. In compensation for their time and effort, participants were offered to keep the weighted blanket and fitness tracker (total value ~\$130.00). In addition, participants who completed all study sessions were mailed a \$20.00 gift card.

Participants with chronic pain were recruited using Research Match, a secure national registry that connects research volunteers with studies. A message with the headline “Do you have a chronic pain diagnosis and are you interested in trying a weighted blanket?” was sent to a random sample of potential volunteers who listed a chronic pain diagnosis in their profile (the study ad was not visible to anyone who had not previously registered with a diagnosis of chronic pain). The study team contacted interested individuals by email with additional information about the study and a link to complete an online screening survey in REDCap to determine eligibility.

Individuals were eligible if they were at least 18 years of age, fluent in English, diagnosed with chronic pain, willing to sleep with a weighted blanket and a fitness watch for one week, able to safely lift at least 15 lbs (6.8 kg), and willing to use their personal smartphone and data plan to complete study assessments. Individuals were excluded if they were pregnant, had a major medical condition, were current or previous users of a weighted blanket, or were claustrophobic.

## Sample Size Determination

Sample size determination was based on previous studies of weighted blankets for anxiety<sup>24</sup> and sleep<sup>2</sup> and was calculated using G\*power version 3.1.9.7. Based on the effect size estimated from data for changes in sleep quality of Cohen’s  $d = 0.75$ <sup>2</sup>, two independent groups,  $\alpha = 0.05$ , and power = 0.80, we determined the current study would require 48 participants in each group. This value was rounded up to  $n = 50$  in each group for a total of  $N = 100$ . However,  $N = 135$  was approved by the IRB to account for study dropout. The trial was stopped once we reached our targeted sample size of 100 completed participants. We were approved to analyze data from all completed participants.

## Randomization and Blinding

Participants were randomized with replacement, stratified by sex, to two weighted blanket groups of

equal size using an Excel-based random number generator programmed by the investigators. Allocation was concealed as the research coordinator accessed this random number generator at the moment of each random assignment, to assign participants to either intervention. Only the research coordinator accessed the LifeData System (see Ecological Momentary Assessment) and the enrollment logs. Further, all assessments were conducted remotely and digitally; there was no interaction between participants and investigators (other than the research coordinator). Study investigators (aside from the coordinator) were thus considered blinded. However, final data analysis was not conducted in a blinded manner. In order to blind participants to the blanket weight manipulation, all participants were told that they would be receiving a “weighted blanket” in the mail. Participants were informed that various blanket weights would be used in the study, but were not informed about the specific blanket weights used, or whether their blanket was heavier or lighter than others in the study.

### **Weighted Blankets**

Participants were randomly assigned to receive a 15-pound [lb.; 6.8 kilograms (kg)] “heavy” weighted blanket or a 5-lb (2.3 kg) “light” weighted blanket – similar to weights employed by Ekholm et al.<sup>41</sup> The light weighted blanket served as an active control condition to control for widespread body contact and blanket-related positive outcome expectancies. All blankets were commercially available (SensaCalm, Chattanooga, TN), grey, twin-sized (38” x 72”), and made from a cotton and/or polyester blend. Blankets were weighted with hypoallergenic, non-toxic glass beads evenly distributed across the blanket, thus providing consistent, widely distributed pressure stimulation across the body. Weighted blankets are considered wellness devices and are not regulated by the U.S. Food and Drug Administration.

### **Ecological Momentary Assessment (EMA)**

The present study employed smartphone-based EMA<sup>33,79,105</sup> methods to remotely guide participants through the study and capture momentary daily changes in study ratings (see Measures). After enrollment, participants received a study manual that supplied detailed instructions on how to download and complete assessments within the LifeData System ([www.lifedatacorp.com](http://www.lifedatacorp.com)), a HIPAA compliant web-based system designed for human subjects research that is compatible with all smartphones. Daily automated prompts to complete study procedures and ratings were sent each morning to participants’ personal smartphones using the LifeData System. Participants were instructed to delay their responses if it would be inappropriate to respond when a prompt was received (eg, when driving).

## **Measures**

### **EMA Items**

EMA items assessed 1) chronic pain intensity (“Please rate your current level of pain”),<sup>125</sup> 2) state anxiety (“Please rate your current level of anxiety”) <sup>1</sup>, 3) sleep quality (“Please rate your quality of sleep last night”), 4) blanket-related pain expectations (“Please rate how you expect the weighted blanket will affect your pain, if at all”), 5) blanket pleasantness (“Please rate pleasantness of the weighted blanket”), and 6) blanket use (“Please rate how much of the night you wore the weighted blanket”). Items were displayed on a 100-point visual analog scale (VAS) ranging from 1 = “no pain and/or extremely anxious and/or extremely poor and/or increase pain a lot and/or extremely unpleasant and/or not at all” to 100 = “worst pain ever and/or extremely calm and/or extremely good and/or decrease pain a lot and/or extremely pleasant and/or all of the night,” respectively. For ease of interpretation, pleasantness ratings were rescaled from 1 = “extremely unpleasant”, 100 = “extremely pleasant” to -100 = “extremely unpleasant,” 0 = “neutral,” 100 = “extremely pleasant.” VASs appeared on participants’ smartphone devices and moved horizontally via tapping from left to right. Numerical values were not visible to participants. A free entry prompt was provided to report medication use (“Please list any regular, daily medications [prescribed or not] you have taken this week for pain [if possible, list dosage as well]”).

### **Quantitative Sleep Measurement**

Participants received a consumer-based, wristwatch fitness tracker (LETSCOM ID115 U HR Fitness Tracker) to wear around the wrist of their nondominant hand during the weeklong trial. The fitness tracker provided an exploratory, quantitative measurement of the amount of time spent in deep and light sleep, as well as heart rate (not reported here due to poor data quality). The device estimates sleep stages using a combination of movement and heart rate patterns. Sleep is determined after detecting inactivity for one hour. During sleep, the device tracks changes in heart rate variability to determine stages of light and deep sleep. After enrollment, participants received a study manual that supplied detailed instructions on how to setup the fitness tracker, download the corresponding smartphone-based application, and upload nightly sleep data to the LifeData System. A ratio of deep to light sleep was calculated for statistical analyses; values greater than 1 indicated more time spent in deep relative to light sleep.

### **Psychological Assessments**

The Pain, Enjoyment of Life, and General Activity Scale (PEG).<sup>86</sup> The PEG<sup>86</sup> is a three-item questionnaire derived from the Brief Pain Inventory<sup>28</sup> that measures global chronic pain intensity (“What number best describes your pain on average in the past week”), and pain interference with enjoyment of life (“What

#### 4 The Journal of Pain

number best describes how, during the past week, pain has interfered with your enjoyment of life”) and general activities (“What number best describes how, during the past week, pain has interfered with your general activity”). Items were measured on an 11-point scale ranging from 0 = “no pain and/or does not interfere” to 10 = “pain as bad as you can imagine and/or completely interferes,” respectively. Items were averaged into a total score with higher values indicating greater pain intensity and interference (session 1  $\alpha = .89$ , session 3  $\alpha = .90$ ).

The State Trait Anxiety Inventory (STAI). The current study employed the STAI<sup>142</sup> Trait version (STAI-T), which is a widely used 20-item scale that measures generalized, long-standing feelings of anxiety [the STAI State version was not measured]. Participants rated items, such as “I feel strained” and “I am relaxed (reversed scored)” on a four-point scale ranging from 1 = “not at all” to 4 = “very much so.” Items were summed into a composite score with higher values indicating greater trait anxiety ( $\alpha = .94$ ).

Debriefing Questionnaire. At the end of the study, participants completed a debriefing questionnaire to assess the degree to which they had insight into the weighted blanket they received. Participants reported whether they believed their blanket was “much lighter than expected, weighed as expected, or was much heavier than expected” on a 100-point VAS. Participants also reported which weighted blanket they believed they had received.

Additional social and psychological measures were collected that were not included in the present analyses.

## Procedure

### Session 1 (Pre-Intervention)

After providing informed consent, participants were contacted via email with instructions for downloading the LifeData smartphone application. During session 1, participants completed EMA items on medication use and blanket-related pain expectations. After providing EMA ratings, participants were directed to REDCap to report demographical information (age, sex, race, height, weight, medical and pain diagnoses) and complete the PEG and STAI. Upon completing session 1, participants were randomized by the research coordinator to receive a heavy weighted blanket or a light weighted blanket and a fitness tracker by mail.

### Pre-Blanket Wearing Nights

Participants were instructed to sleep while wearing the fitness tracker (no weighted blanket) around the wrist of their nondominant hand for three nights and complete EMA ratings assessing chronic pain intensity, anxiety, and sleep quality each morning. EMA prompts also requested participants to upload their sleep tracker data from the previous night.

An RCT of weighted blankets for chronic pain

### Session 2 (Brief Trial)

Session 2 was an initial brief trial of the weighted blanket and was initiated in the LifeData application when participants indicated they had received their weighted blanket and were ready to complete assessments. During session 2, participants provided EMA ratings of pain intensity, anxiety, and expectations. Participants were then instructed to lie down for 15 minutes while wearing the fitness tracker, without the weighted blanket. Next, participants were instructed to lie down again and wear the fitness tracker and weighted blanket for an additional 15 minutes. Participants then provided EMA ratings of pain intensity, anxiety, and blanket pleasantness.

### Blanket-Wearing Nights (Weeklong Trial)

After completing session 2, participants were instructed to sleep while wearing the fitness tracker and weighted blanket for seven nights and complete EMA ratings of pain intensity, anxiety, sleep quality, and blanket use each morning. Daily EMA prompts also requested participants to upload their sleep tracker data from the previous night.

### Session 3 (Post-Intervention)

Immediately after completing the seventh day of blanket EMA ratings, participants were asked to complete session 3 assessments. For participants who did not complete the session immediately, frequent reminders were sent allowing study completion for up to two weeks. During session 3, participants completed EMA items on medication use. After providing EMA ratings, participants were directed to REDCap to complete the PEG. At the end of the session, participants completed the debriefing questionnaire.

## Debriefing

One week after the last participant completed the study, the study coordinator emailed participants to debrief them on their participation. The email stated 1) the study purpose, 2) that two weighted blankets, 5 and 15-lbs, were used in the study, 3) a brief summary of study findings, and 4) the blanket weight they received.

## Statistical Analyses

All analyses were conducted in SPSS Version 26 (IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp). The study purpose, targeted condition, study design, and primary and secondary outcomes were pre-registered in ClinicalTrials.gov (NCT04447885: “Weighted Blankets and Chronic Pain”). The *preregistered* primary outcome was change in chronic pain ratings from before to after wearing a weighted blanket during the brief and weeklong blanket trials, respectively. For the weeklong trial, we compared pre-blanket wearing VAS ratings (average pain VAS rating from the 3 pre blanket wearing nights) to the final night of weighted blanket use (pain VAS rating from the morning after night 7 of blanket wearing). Pre- and post-



blanket wearing pain ratings were compared in a 2 (time: pre, post)  $\times$  2 (group: light blanket, heavy blanket) repeated measures (RM) analysis of covariance (ANCOVA), after adjusting for trait anxiety and expectations. We covaried session 2 expectations because they were measured immediately after participants saw and felt their blankets for the first time, thus providing a better assessment of their perceived effectiveness of the blanket rather than an appraisal of the effectiveness of weighted blankets in general for pain relief. The preregistered secondary outcomes included changes in anxiety and sleep from before to after wearing a weighted blanket during the brief (anxiety only) and weeklong blanket trials, and were entered into 2  $\times$  2 RM ANCOVAs, controlling for trait anxiety. For all ANCOVAs, post hoc tests were conducted using the Bonferroni correction to determine the nature of significant time  $\times$  group interactions. For the brief trial, we compared pre- (15 minutes before wearing weighted blanket) to post-intervention (after wearing the weighted blanket for 15 minutes) VAS ratings. PEG scores were also compared pre (session 1) to post-intervention (session 3). Normality assumption for ANOVA was examined using the skewness and kurtosis indices on repeated measures within each group. All key study variables were within normal ranges, justifying the use of parametric tests. A significance criterion of  $P < .05$  was employed.

Mediation and moderation hypotheses were not preregistered. Mediation models tested for an indirect effect of weighted blanket group on pain reductions via blanket-related changes in anxiety and sleep, respectively. Models were estimated with an ordinary least squares (OLS) path analytic framework implemented in the SPSS PROCESS Macro Version 3.4 (Model 4).<sup>69,124</sup> Significance of indirect effects was predicated on bias-corrected bootstrapped approximations with 5,000 iterations and 95% bias-corrected confidence intervals. Trait anxiety and session 2 expectations were entered as covariates in all mediation models. Lastly, moderation analysis was also implemented in PROCESS (Model 1) to explore the boundary conditions by which blanket pressure influenced pain reductions as a function of trait anxiety, adjusting for expectations. Pain, anxiety, and sleep difference scores (ie, post - pre), respectively, were computed and entered in mediation and moderation models as appropriate. Assumptions for OLS (normality; linearity; absence of multicollinearity; homoscedasticity) were met before estimating models. A significance criterion of  $P < .05$  was employed.

## Results

### Participant Flow Through the Study

A total of 211 individuals were assessed for eligibility, 118 were randomized to the intervention (53 to heavy blanket and 65 to light blanket), 16 were lost to follow-up (2 heavy blanket and 14 light blanket), and 8 were excluded after randomization but prior to analysis based on two criteria: 1) baseline PEG scores were less than 4

( $n = 7$ ), indicating a "mild" level of pain – a criterion employed in previous research,<sup>100</sup> and 2) weighted blanket was reported to be worn less than 30% of each night on average, over the weeklong trial ( $n = 1$ ), leaving 94 in the final sample (47 in each group; see CONSORT diagram).

### Sample Characteristics

The total sample consisted of 94 participants [age  $M = 43.8$ ,  $SD = 12.8$  years, range = 19-69;  $n = 75$  (80%) female;  $n = 81$  (86%) White,  $n = 8$  (9%) Black,  $n = 4$  (4%) Hispanic and/or Latino,  $n = 1$  (1%) other] from 33 states and territories in the US. Participants' average body mass index (BMI) was 31.6 ( $SD = 10.3$ ; range = 17.6-75.1). See Table 1 for study demographics and baseline ratings. Overall, participants reported "moderate" levels of pain at baseline across all levels of analysis. After initial use, both the light ( $M = 26.7$ ,  $SD = 35.5$ ) and heavy ( $M = 35.2$ ,  $SD = 43.4$ ) weighted blankets were rated as mildly to moderately pleasant [ $t(92) = -1.0$ ,  $P = .30$ ], at levels similar to our previous research on pleasant gentle stroking and deep pressure.<sup>20</sup> At the end of the study, when asked which blanket participants believed they had received, 68% of participants in the light weighted blanket group accurately guessed they had received a light blanket (15% had "no idea"), and 62% of participants in the heavy weighted blanket group accurately guessed they had received a heavy blanket (25% had "no idea") [ $\chi^2(2, N = 94) = 42.9$ ,  $P < .001$ ].

Two pain physicians at UC San Diego (NMS and KAB) independently categorized participant-reported diagnoses of chronic pain based on published standards,<sup>34,144,145</sup> with a third pain physician serving as tie-breaker (JPC). The majority of the sample consisted of participants with chronic primary pain ( $n = 57$ , 61%) and secondary musculoskeletal pain ( $n = 57$ , 61%), followed by neuropathic pain ( $n = 18$ , 19%). A relatively smaller proportion of participants had secondary visceral pain ( $n = 7$ , 7%), cancer-related pain ( $n = 2$ , 2%), posttraumatic / post-surgical pain ( $n = 1$ , 1%), and secondary headache and/or orofacial pain ( $n = 1$ , 1%). Many participants ( $n = 38$ , 40%) had chronic pain diagnoses that met the criteria for more than one diagnostic category.

### Basic Relationships and Covariate Selection

Descriptive statistics and bivariate correlations among pain, anxiety, and sleep constructs are summarized in Table 2. Higher trait anxiety was correlated (medium to large effect sizes) with several outcome measures, two of which survived a more conservative Bonferroni corrected  $p$ -value for multiple comparisons (employed to reduce the risk of type 1 error), computed as  $\alpha = .05$  divided by  $k$  number of comparisons ( $k = 18$ ; Bonferroni adjusted  $P$  value = .0003).<sup>31</sup> Therefore, trait anxiety was selected as a covariate in subsequent analyses. In addition, session 2 expectations were controlled for to isolate effects of blanket pressure independent from placebo expectancy effects. Although not displayed in Table 2, age and BMI were not significantly correlated

**Table 1. Sample Characteristics and Baseline Ratings for the Heavy and Light Blanket Groups.**

VARIABLE		TOTAL N = 94		HEAVY BLANKET (15 LB) N = 47		LIGHT BLANKET (5 LB) N = 47	
		N (%)	M (SD)	N (%)	M (SD)	N (%)	M (SD)
Sex	Female	75 (80%)		36 (76%)		39 (83%)	
	Male	16 (17%)		10 (21%)		6 (13%)	
	Unspecified	3 (3%)		1 (2%)		2 (4%)	
Age			43.83 (12.78)		45.83 (12.46)		41.83 (12.92)
Chronic Pain Category							
	Primary	57 (61%)		27 (57%)		30 (64%)	
	Cancer-related	2 (2%)		2 (4%)		0 (0%)	
	Neuropathic	18 (19%)		7 (15%)		11 (23%)	
	Visceral	7 (7%)		3 (6%)		4 (9%)	
	Posttraumatic / Surgical	1 (1%)		0 (0%)		1 (2%)	
	Headache / Orofacial	1 (1%)		1 (2%)		0 (0%)	
	Musculoskeletal	57 (61%)		27 (57%)		30 (64%)	
Medication Category							
	Opioids	40 (42%)		20 (42%)		20 (42%)	
	NSAIDs	40 (42%)		19 (40%)		21 (45%)	
	Acetaminophen	38 (40%)		21 (45%)		17 (36%)	
	Antidepressants	15 (16%)		10 (21%)		5 (11%)	
	Anticonvulsants	23 (24%)		14 (30%)		9 (19%)	
	Triptans	2 (2%)		1 (2%)		1 (2%)	
	Cannabinoids	7 (7%)		3 (6%)		4 (9%)	
	Antispasmodics	19 (20%)		10 (21%)		9 (19%)	
Baseline Ratings							
	Pain Intensity VAS	94	62.3 (14.7)		63.2 (14.8)		61.4 (14.7)
	PEG	94	6.7 (1.3)		6.9 (1.3)		6.6 (1.4)
	Anxiety VAS	94	45.2 (21.8)		48.8 (22.9)		41.6 (20.1)
	Sleep Quality VAS	94	38.5 (16.3)		36.5 (16.5)		40.4 (16.1)
	Trait Anxiety	94	50.7 (11.4)		48.5 (11.5)		53.0 (10.9)
	S1 Expectations VAS	93	62.7 (13.6)		62.7 (16.6)		62.7 (10.2)
	S2 Expectations VAS	94	58.1 (12.3)		57.5 (14.7)		58.8 (9.7)

VAS, visual analog scale; PEG, Pain, Enjoyment of Life, and General Activity Scale; S1, session 1; S2, session 2.

**Table 2. Descriptive Statistics and Bivariate Correlations Among key Study Variables**

VARIABLE	N	M (SD)	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
1. Group	94																		
2. S1 PEG	94	6.7 (1.3)	.1																
3. S1 expect.	93	62.7 (13.6)	.0	.1															
4. Trait anx.	94	50.7 (11.4)	-.2	.5**	.0														
5. Pre pain VAS	94	56.9 (13.7)	.0	.5**	.1	.3**													
6. Pre anx. VAS	94	54.2 (14.7)	.0	.3**	.1	.4**	.3**												
7. Pre sleep qual. VAS	94	38.5 (16.3)	-.1	-.3*	.1	-.3**	-.2	-.2*											
8. Pre deep : light	88	.7 (.4)	-.2	-.0	.1	.1	.2	-.1	.2*										
9. S2 pre pain VAS	94	59.2 (16.7)	-.1	.3**	-.1	.1	.6**	.1	-.1	.2									
10. S2 pre anx. VAS	94	59.2 (17.5)	-.2*	.2*	.0	.3**	.2	.4**	.0	-.0	.2								
11. S2 pre expect.	94	58.1 (12.3)	-.1	-.2*	.6**	-.1	-.1	.1	.0	.1	-.1	-.0							
12. S2 post pain VAS	93	51.2 (16.2)	-.2	.3*	-.2	.1	.4**	.1	.0	.1	.6**	.1	-.2*						
13. S2 post anx. VAS	94	48.1 (17.4)	-.3*	.1	-.1	.3**	.1	.2*	.1	.1	.5**	-.2	.4**						
14. S3 PEG	94	5.7 (1.8)	-.1	.6**	-.1	.3*	.3**	.1	-.1	.0	.3**	.1	-.2*	.5**	.2*				
15. Night 7 pain VAS	87	45.7 (19.8)	-.2	-.2	.1	.0	-.1	.0	.1	-.0	-.0	.0	.1	-.1	-.0	-.4**			
16. Night 7 anx. VAS	87	51.3 (18.4)	-.1	.1	-.0	.2*	.3**	.3*	.1	.2	.1	.3*	-.1	.3**	.4**	.4**	-.3**		
17. Night 7 sleep qual. VAS	87	44.9 (23.1)	-.1	.0	.1	-.1	-.1	.0	.1	-.1	-.2	.1	-.0	-.2	-.1	-.2*	.5**	-.5**	
18. Night 7 deep : light	67	.7 (.4)	-.4**	-.2	-.0	-.0	.0	.0	.2	.6**	.1	-.0	-.1	.0	.0	-.0	.2	.2	.0

S1, session 1; S2, session 2; S3, session 3; PEG, Pain, Enjoyment of Life, and General Activity Scale; VAS, visual analog scale.

Note. Group was coded as 0 = light weighted blanket, 1 = heavy weighted blanket.

Deep : light = ratio of the amount of time spent in deep relative to light sleep. Values greater than 1 indicate more time spent in deep relative to light sleep.

\*P < .05.

\*\*P < .001. Bolded values indicate relationships that survived Bonferroni correction (P < .003).

Baumgartner et al

with any outcome measures ( $ps > .05$ ), and therefore were not entered as covariates.

### **No Significant Difference Between Heavy and Light Weighted Blanket in Pain Intensity VAS Rating Reductions (Preregistered Primary Outcome)**

Brief weighted blanket trial (session 2): A  $2 \times 2$  RM ANCOVA controlling for trait anxiety and session 2 expectations revealed a non-significant main effect of time ( $F(1, 90) = .9, P = .36$ ), group ( $F(1, 90) = 1.4, P = .23$ ), and time  $\times$  group interaction ( $F(1, 90) = 1.4, P = .24$ , Cohen's  $f = .07$ ) on chronic pain intensity VAS ratings from before to after 15 minutes of blanket wearing (covariates,  $ps > .05$ ; Table 3, Fig 1A).

Weeklong weighted blanket trial: Chronic pain intensity VAS ratings were compared between blanket groups from before to after the weeklong trial of blanket wearing, controlling for trait anxiety and expectations. As with brief pain ratings, neither the main effect of time ( $F(1, 83) = .0, P = .85$ ), group ( $F(1, 83) = .8, P = .37$ ), nor the time  $\times$  group interaction was significant ( $F(1, 83) = 2.3, P = .14, f = .12$ ; covariates,  $ps > .05$ ; Table 3, Fig 1B).

In a series of exploratory (not preregistered) one-way ANCOVAs, we compared blanket-related chronic pain intensity reductions (i.e., difference scores) within the three most frequent pain diagnostic categories – primary, musculoskeletal, and neuropathic pain – controlling for trait anxiety and expectations. One-way ANCOVAs were employed due to patient overlap in diagnostic categories. Pain intensity reductions were largest in the heavy weighted blanket group ( $M_{diff} = -15.9, SD_{diff} = 23.8$ ) relative to the light weighted blanket group ( $M_{diff} = -3.9, SD_{diff} = 26.8$ ) in participants with musculoskeletal pain ( $F(1, 51) = 4.8, P = .03$ , Cohen's  $d = .47$ ;  $M_{diff} = -15.9, SEM = 7.3$ ), whereas there were no significant differences between groups for participants with primary or neuropathic pain ( $Ps > .05$ ; Fig 1C; covariates,  $Ps > .05$ ).

Across all pain intensity analyses, patterns of results were unchanged after statistically accounting for opioid medication use and study completion date.

### **Heavy Weighted Blanket Reduces PEG Pain Ratings Significantly More Than the Light Weighted Blanket**

To test effects of pressure on broader pain perceptions, we also examined changes in chronic pain intensity and interference as measured by the PEG after the weeklong trial. A RM ANCOVA controlling for trait anxiety and expectations revealed non-significant effects of time ( $F(1, 90) = .8, P = .38$ ) and group ( $F(1, 90) = .6, P = .46$ ) on PEG ratings. However, there was a significant time  $\times$  group interaction ( $F(1, 90) = 4.5, P = .04, f = .19$ ), which was associated with significantly reduced PEG pain ratings in the heavy weighted blanket group ( $M_{diff} = -1.4, SEM = .2, P < .001, 95\% CI [-2.0, -.9]$ ) and, to a lesser degree, in the light weighted blanket group

( $M_{diff} = -.7, SEM = .2, P < .01, 95\% CI [-1.1, -.3]$ ) (Table 3, Fig 2A; covariates,  $ps > .05$ , time  $\times$  STAI,  $F(1,90) = 3.4, P = .07, f = .16$ ).

Exploratory one-way ANCOVAs controlling for trait anxiety and expectations were conducted to compare blanket-related PEG reductions within primary, musculoskeletal, and neuropathic pain categories. PEG reductions were largest in the heavy weighted blanket group ( $M_{diff} = -1.64, SD_{diff} = 1.62$ ) relative to the light weighted blanket group ( $M_{diff} = -.9, SD_{diff} = 1.3$ ) in participants with primary pain ( $F(1, 57) = 4.3, P = .04, d = .49$ ;  $M_{diff} = -.8, SEM = .4$ ), whereas there were no significant differences between groups for participants with musculoskeletal or neuropathic pain ( $ps > .05$ ; Fig 2B; covariates,  $Ps > .05$ ).

Patterns of results were unchanged after statistically accounting for opioid medication use and study completion time. The mean number of days elapsed between the end of the weeklong trial to session 3 completion was low,  $M = 1.7, SD = 2.32$ , and did not differ between groups  $t(92) = 1.5, P = .13$ . In addition, including these data as a nuisance variable did not alter results. Due to the non-significant effect of blanket pressure on pain intensity VAS ratings, we performed supplementary analyses on the 3 item PEG scale to evaluate the degree to which the overall PEG effect was driven by its two subcomponents, pain intensity or pain interference, respectively. PEG interference items (2-3) were averaged into a single score for session 1 and session 3, respectively, and entered into a RM ANCOVA, excluding the pain intensity item (item 1), controlling for trait anxiety and expectations. The main effect of time ( $F(1, 89) = .3, P = .57$ ), group ( $F(1, 89) = .4, P = .53$ ), and interaction ( $F(1, 89) = 2.5, P = .14$ ) were non-significant (covariates,  $P > .05$ ), suggesting that pain intensity played a role in the overall PEG effect. We also conducted this analysis in the subgroup of patients with chronic primary pain. Here, we found that the overall PEG effect was largely maintained for the average PEG interference items ( $F(1, 57) = 3.9, P = .05, d = .49$ ).

### **Deep Pressure Elicits Greater Pain Relief in Participants with High Trait Anxiety**

The overall model assessing the moderating effect of trait anxiety in the association between blanket group and PEG reductions, controlling for expectations, was significant ( $F(4, 89) = 3.3, P = .01, R^2 = .13$ ). Importantly, the interaction between blanket group and trait anxiety on PEG reductions was also significant ( $b = -.1, SEM = .0, P = .02, 95\% CI [-.12, -.01]$ ), providing evidence for a conditional effect. As depicted in Fig 3, the heavy weighted blanket produced greater PEG reductions in participants who reported "medium" ( $M = 50.7, b = -.7, SEM = .3, P = .03, 95\% CI [-1.3, -.1]$ ) or "high" ( $+1SD = 62.1, b = -1.4, SEM = .4, P < .01, 95\% CI [-2.3, -.5]$ ) levels of trait anxiety ["low" ( $-1SD$ ) trait anxiety,  $P = .85$ ]. In contrast, chronic pain reductions were relatively unaffected by the light weighted blanket across all levels of trait anxiety. The Johnson-Neyman technique<sup>70</sup> revealed that the value of trait anxiety where the conditional effect

**Table 3. ANCOVAs Assessing Between Group Differences in Primary and Secondary Outcomes**

DIAGNOSTIC CATEGORY	BLANKET	PAIN INTENSITY VAS						PEG		
		S2 PRE	S2 POST	N	PRE-BLANKET	NIGHT 7	N	S1	S3	N
All	Heavy	58.1 (16.3)	48.8 (13.9)	47	56.3 (11.9)	42.8 (19.6)	43	6.9 (1.3)	5.6 (1.6)*	47
	Light	60.2 (17.2)	53.7 (17.8)	47	56.3 (14.9)	48.8 (19.7)	44	6.6 (1.4)	5.8 (1.9)	47
Primary	Heavy	56.6 (18.0)	47.2 (14.2)	27	56.2 (13.8)	47.2 (19.2)	25	7.1 (1.2)	5.5 (1.5)**	27
	Light	60.6 (16.9)	53.6 (19.1)	30	57.8 (15.7)	45.8 (19.9)	29	6.8 (1.4)	5.8 (2.1)	30
Neuropathic	Heavy	56.4 (15.5)	47.7 (18.2)	7	59.4 (8.5)	45.2 (20.7)	6	6.9 (1.2)	5.2 (2.0)	7
	Light	62.6 (13.9)	56.1 (12.9)	11	56.9 (12.7)	43.2 (16.2)	11	7.3 (1.1)	6.6 (1.7)	11
Cancer-related	Heavy	63.0 (7.1)	57.0 (11.3)	2	56.8 (9.7)	60.5 (2.1)	2	5.7 (1.9)	3.7 (2.4)	
	Light	—	—	0	—	—	0	—	—	
Visceral	Heavy	57.7 (17.0)	50.0 (10.5)	4	56.1 (14.7)	12.7 (20.2)	3	6.6 (1.0)	7.0 (.3)	4
	Light	76.0 (4.1)	57.8 (19.2)	3	64.3 (11.6)	53.3 (24.9)	3	6.8 (1.9)	5.9 (1.7)	3
Posttraumatic / Surgical	Heavy	—	—	0	—	—	0	—	—	0
	Light	77.0	27.0	1	37.0	32.0	1	5.3	5.3	1
Headache / Orofacial	Heavy	74.0	40.0	1	49.0	1.0	1	5.7	6.7	1
	Light	—	—	0	—	—	0	—	—	0
Musculoskeletal	Heavy	57.7 (16.7)	50.2 (14.7)	27	52.5 (14.6)	37.6 (16.9)**	23	6.7 (1.3)	5.7 (1.7)	26
	Light	59.2 (17.2)	52.3 (18.3)	30	54.5 (14.6)	50.7 (20.5)	27	6.6 (1.5)	5.93 (2.1)	30

		ANXIETY VAS					
		S2 PRE	S2 POST	N	PRE-BLANKET	NIGHT 7	N
All	Heavy	55.4 (18.3)	43.7 (17.4)	47	54.4 (16.1)	49.7 (18.7)	44
	Light	62.9 (16.0)	52.4 (16.4)	47	54.5 (13.9)	52.9 (18.2)	43
Primary	Heavy	54.4 (17.4)	41.0 (14.7)	27	57.4 (14.1)	48.0 (17.5)	25
	Light	66.5 (15.9)	54.1 (15.9)	30	55.8 (15.5)	51.1 (19.7)	
Neuropathic	Heavy	57.3 (14.5)	46.3 (15.9)	7	53.0 (10.8)	48.2 (15.6)	6
	Light	60.8 (19.6)	52.5 (13.3)	11	53.7 (14.1)	49.8 (15.9)	11
Cancer-related	Heavy	49.0 (18.4)	45.5 (3.5)	2	44.3 (19.2)	55.0 (5.7)	2
	Light	—	—	0	—	—	0
Visceral	Heavy	70.0 (30.5)	65.7 (21.7)	4	61.3 (30.0)	71.7 (30.9)	3
	Light	56.5 (18.7)	48.0 (12.3)	3	46.2 (9.8)	46.0 (4.4)	3
Posttraumatic / Surgical	Heavy	—	—	0	—	—	0
	Light	71.0	14.0	1	42.0	57.0	1
Headache / Orofacial	Heavy	79.0	74.0	1	44.3	78.0	1
	Light	—	—	0	—	—	0
Musculoskeletal	Heavy	54.1 (18.9)	43.9 (17.9)	27	49.9 (17.3)	49.5 (17.9)	24
	Light	63.8 (16.3)	53.6 (18.9)	30	54.2 (14.9)	56.0 (18.1)	27

		SLEEP QUALITY VAS			DEEP : LIGHT SLEEP		
		PRE-BLANKET	NIGHT 7	N	PRE-BLANKET	NIGHT 7	N
All	Heavy	36.3 (15.6)	42.8 (25.8)	44	.6 (.3)	.6 (.3)	36
	Light	40.9 (15.9)	47.1 (20.2)	43	.8 (.6)	.9 (.5)	30
Primary	Heavy	35.4 (16.1)	48.1 (28.1)	25	.6 (.3)	.6 (.3)	20
	Light	37.9 (15.3)	45.9 (19.8)	29	.8 (.3)	.8 (.4)	19
Neuropathic	Heavy	35.7 (9.9)	46.3 (27.5)	6	.7 (.3)	.8 (.3)	4
	Light	44.8 (15.6)	54.6 (15.5)	11	.9 (.9)	.7 (.5)	9
Cancer-related	Heavy	49.3 (16.9)	53.0 (16.9)	2	.5 (.1)	.5 (.0)	2
	Light	—	—	0	—	—	0
Visceral	Heavy	32.1 (26.0)	19.0 (18.0)	3	.8 (.6)	.5 (.2)	2
	Light	22.6 (17.0)	25.3 (12.1)	3	.8 (.4)	1.1 (.4)	3
Posttraumatic / Surgical	Heavy	—	—	0	—	—	0
	Light	58.5	12.0	1	1.9	1.6	1
Headache / Orofacial	Heavy	59.3	19.0	1	.7	.4	1
	Light	—	—	0	—	—	0
Musculoskeletal	Heavy	34.7 (14.9)	39.7 (20.9)	24	.6 (.3)	.6 (.3)	20
	Light	41.3 (16.7)	46.8 (20.3)	27	.9 (.7)	.8 (.6)	18

S1, session 1; S2, session 2; S3, session 3; PEG, Pain, Enjoyment of Life, and General Activity Scale; VAS, visual analog scale.

Note. Means and standard deviations are displayed.


Covariates = trait anxiety and session 2 expectations.

Deep : light sleep ratio values greater than 1 indicate more time spent in deep relative to light sleep.

\**P* < .05,

\*\**P* < .001, indicates significance level at which groups differed.





**Figure 1.** Changes in ratings of chronic pain intensity before and after use of a light or heavy weighted blanket. (A) Mean visual analog scale (VAS) ratings of chronic pain intensity provided during the brief trial (grey bars = pre-blanket wearing, green bars = post-blanket wearing) of the heavy weighted blanket or light weighted blanket are displayed. However, the time  $\times$  group interaction was non-significant. (B) Mean VAS ratings of chronic pain intensity provided during the weeklong trial (grey bars = pre-blanket wearing, green bars = post-blanket wearing) of the heavy or light weighted blanket are displayed. However, the time  $\times$  group interaction was non-significant. (C) Mean changes in VAS pain intensity ratings from baseline to night 7 of weighted blanket use within diagnostic categories of primary pain, musculoskeletal pain, and neuropathic pain are displayed. Pain intensity reductions were greatest in the heavy weighted blanket group relative to the light weighted blanket group in participants with musculoskeletal pain, whereas there were no significant differences between groups for participants with primary or neuropathic diagnoses. All pain intensity ratings were collected on a 0 (no pain) to 100 (worst pain ever) VAS scale. All values displayed are adjusted for session 2 expectations and trait anxiety. Asterisks indicate significance differences at the  $*P < .05$  level. Color version of figure is available online.


became statistically significant was 49.9 ( $b = -.61$ ,  $SEM = .31$ ,  $P = .05$ ). In the current sample, 56% of participants had trait anxiety sums above this value.

These results were unchanged after accounting for other potential contributing factors, including opioid medication use, study completion date, session 3 completion, and baseline PEG levels.

### Weighted Blankets do not Significantly Improve Anxiety or Sleep (Preregistered Secondary Outcomes)


#### Anxiety

A  $2 \times 2$  RM ANCOVA controlling for trait anxiety revealed a non-significant effect of time ( $F(1, 91) = .5$ ,



**Figure 2.** Changes in chronic pain PEG scores before and after use of a light or heavy weighted blanket. (A) Mean Pain, Enjoyment of Life, and General Activity Scale (PEG) scores collected during baseline and after one week of use for the heavy weighted blanket and light weighted blanket are displayed. Both blanket groups significantly reduced PEG scores from baseline (session 1; grey bars) to one week (session 3; green bars). However, PEG reductions were significantly greater in the heavy weighted blanket group than in the light weighted blanket group. (B) Mean changes in PEG scores from baseline to after one week of use within diagnostic categories of primary pain, musculoskeletal pain, and neuropathic pain are displayed. PEG reductions were greatest in the heavy weighted blanket group relative to the light weighted blanket group in participants with primary pain, whereas there were no significant differences between groups for participants with musculoskeletal or neuropathic pain. The PEG measured pain intensity and interference on a 0 (no pain and/or does not interfere) to 10 (pain as bad as you can imagine and/or completely interferes) scale. PEG scores are displayed after adjusting for session 2 expectations and trait anxiety. Asterisks indicate significance differences at the  $*P < .05$ ,  $**P < .01$ , and  $****P < .0001$  levels. Color version of figure is available online.

$P = .50$ ) on anxiety VAS ratings from before to after 15-minutes of blanket wearing. There was a significant main effect of group ( $F(1, 91) = 4.44$ ,  $P = .04$ ,  $f = .19$ ), with anxiety VAS ratings being significantly lower in the heavy weighted blanket group on average than the light weighted blanket group ( $M_{diff} = -6.3$ ,  $SEM = 2.98$ ,  $P = .04$ , 95% CI [-12.2, -.4]). However, the time  $\times$  group interaction was non-significant ( $F(1, 91) = .2$ ,  $P = .68$ ; covariate,  $P > .05$ ; Table 3, Fig 4A). Likewise, there was no significant effect of time ( $F(1, 84) = .5$ ,  $P = .49$ ), group ( $F(1, 84) = .1$ ,  $P = .78$ ), or time  $\times$  group interaction ( $F(1, 84) = .84$ ,  $P = .36$ ) on anxiety ratings after the weeklong trial (covariate,  $P > .05$ ; Table 3, Fig 4B). One outlier was detected in this analysis using a z score  $\pm 3$  criterion




**Figure 3.** Moderating effect of trait anxiety in the association between blanket weight and chronic pain PEG reductions. There was a significant interaction between weighed blanket group and trait anxiety in predicting Pain, Enjoyment of Life, and General Activity Scale (PEG) <sup>86</sup> reductions. Post hoc probing of this interaction revealed that PEG reductions were significantly greater in the heavy weighted blanket group (dark green line) for chronic pain patients who reported “medium” (mean) and “high” (+1 standard deviation) values of trait anxiety. PEG reductions were unchanged in the light weighted blanket group (light green line). The dotted grey line represents the exact value of trait anxiety where the conditional effect became significant (49.87). The PEG measured pain intensity and interference on a 0 (no pain / does not interfere) to 10 (pain as bad as you can imagine / completely interferes) scale. PEG reductions are displayed after adjusting for session 2 expectations. Asterisks indicate significance differences at the \* $P < .05$  and \*\* $P < .01$  levels. Color version of figure is available online.

(not preregistered); removal of this outlier did not significantly alter results.

## Sleep

Sleep quality VAS ratings after the weeklong trial did not differ as a function of time ( $F(1, 84) = .0, P = .97$ ).




**Figure 4.** Changes in ratings of state anxiety before and after use of a light or heavy weighted blanket. (A) Mean visual analog scale (VAS) ratings of state anxiety collected during the brief trial (grey bars = pre-blanket wearing, green bars = post-blanket wearing) are displayed for the heavy weighted blanket and light weighted blanket groups. However, the time  $\times$  group interaction was non-significant. (B) Mean VAS ratings of state anxiety collected during the weeklong trial in the heavy weighted blanket and light weighted blanket groups are displayed. There were no significant differences in anxiety ratings from the 3-night baseline period (grey bars) to night 7 of weighted blanket use (green bars). Anxiety values are after adjusting for trait anxiety. State anxiety ratings were collected on a 0 (extremely calm) to 100 (extremely anxious) VAS scale. Color version of figure is available online.

There was a significant effect of group ( $F(1, 84) = 4.1, P = .046, f = .19$ ), with sleep quality ratings being significantly lower on average in the heavy weighted blanket group when compared to the light weighted blanket group ( $M_{diff} = -6.4, SEM = 3.2, P = .046, 95\% CI [-12.70, -1.11]$ ). However, the interaction of time with group was non-significant ( $F(1, 84) = .03, P = .86$ ; Table 3, Fig 5A; covariate,  $P > .05$ ). The main effect of time in the ratio of deep to light sleep after accounting for trait anxiety was non-significant ( $F(1, 63) = 2.9, P = .09, f = .17$ ). The main effect of group was significant ( $F(1, 63) = 7.4, P = .01, f = .31$ ), such that participants wearing the light weighted blanket spent more time in deep relative to light sleep on average than the heavy weighted blanket group ( $M_{diff} = .25, SEM = .1, P = .01, 95\% CI [-.43, -.07]$ ). However, the time  $\times$  group interaction was non-significant ( $F(1, 63) = .6, P = .45$ ; Table 3, Fig 5B; covariate,  $P > .05$ ). Two outliers were detected in this analysis using a z score  $\pm 3$  criterion; removal of these outliers did not significantly alter results.

## Anxiety and Sleep did not Significantly Mediate Blanket-Induced Pain Reductions

Mediation analyses tested the hypothesized indirect effects of weighted blanket-related changes in pain via changes in anxiety and sleep, respectively, after controlling for trait anxiety and expectations. However, none of the indirect effects were significant ( $p$ 's  $> .05$ ). Opioid medication use, study completion date, session 3 completion (when PEG was entered as the outcome



**Figure 5.** Sleep quality ratings and deep to light sleep ratio values before and after use of a light or heavy weighted blanket. (A) Mean visual analog scale (VAS) ratings of sleep quality collected during the weeklong trial for the heavy weighted blanket and light weighted blanket groups are displayed. There were no significant changes in sleep quality ratings from the 3-night baseline period (grey bars) to night 7 of weighted blanket use (green bars). Sleep quality ratings were collected on a 0 (extremely poor) to 100 (extremely good) VAS scale. (B) Deep to light sleep ratio values during the weeklong trial are displayed. Ratio values were calculated as the ratio between the average amount of time spent in deep versus light sleep, as measured by a fitness tracker, with values greater than 1 indicating more time spent in deep relative to light sleep. There were no significant differences in deep to light sleep ratio values from the 3-night baseline period (grey bars) to night 7 of weighted blanket use (green bars). Sleep values are after adjusting for trait anxiety. Color version of figure is available online.

variable), and removal of the aforementioned outliers did not alter these results. Table 4 displays a summary of all paths in each model.

**Discussion**

The current study demonstrated a greater effect of a heavy versus light weighted blanket in reducing chronic pain intensity and interference ratings as measured by our secondary pain outcome (PEG)<sup>86</sup>. The effect of weighted blanket pressure on PEG ratings was significant after controlling for trait anxiety and for expectations of pain relief. In contrast, there was no overall effect of weighted blankets on purely sensory aspects of

chronic pain as measured by our primary pain outcome (VAS pain intensity ratings), or any differential effect of greater pressure. This is consistent with studies showing that complementary approaches tend to alleviate the burden of chronic pain without reducing pain intensity.<sup>8,162</sup> These results suggest that deeper pressure from a heavy weighted blanket can reduce social and/or affective components of the chronic pain experience, above and beyond cognitive and placebo effects.

In contrast to our hypotheses, weighted blankets did not significantly alter anxiety or sleep, and changes in these variables were not significant mediators of blanket-related pain reductions. However, it is possible that differences would emerge under different or longer

**Table 4. Summary of Paths for the Hypothesized Indirect Effects of Blanket Group on Pain Reductions via Changes in Anxiety and Sleep**

		PATHS															
Pain DV	Mediator	A (GROUP -> MEDIATOR)				B (MEDIATOR -> PAIN)				DIRECT EFFECT (GROUP -> PAIN)				INDIRECT EFFECT (A * B)			
		b	SEM	t	p	b	SEM	t	p	b	SEM	t	p	b	SEM	LLCI	ULCI
S2 pain VAS diff.	S2 anx. VAS diff.*	-2.0	3.6	-6	.58	.3	.1	3.2	.00	-3.3	2.9	-1.1	.27	-.6	1.0	-2.7	1.4
Pre-Night 7 pain VAS diff.	Pre-Night 7 anx. VAS diff.**	-4.4	4.6	-9	.34	-.3	.1	-2.7	.00	-9.6	5.2	-1.8	.07	1.6	1.7	-1.3	5.5
	Pre-Night 7 sleep qual. VAS diff.†	1.1	5.9	.2	.86	.3	.1	3.0	.00	-8.4	5.1	-1.6	.11	.3	1.9	-3.1	4.5
	Pre-Night 7 deep : light diff.‡	-.1	.1	-6	.54	12.0	7.4	1.6	.11	-7.3	5.6	-1.3	.20	-.7	1.8	-5.8	1.2
S1-S3 PEG diff.	Pre-Night 7 anx. VAS diff.§	-4.4	4.6	-9	.34	.0	.0	3.5	.00	-.6	.3	-1.8	.07	-.1	.1	-.4	.1
	Pre-Night 7 sleep qual. VAS diff.	1.1	5.9	.2	.86	-.0	.0	-3.4	.00	-.7	.3	-2.1	.04	-.0	.1	-.3	.20
	Pre-Night 7 deep : light diff.¶	-.1	.1	-6	.54	-.2	.5	-.5	.63	-.8	.4	-2.1	.04	.0	.1	-.1	.2

S1, session 1; S2, session 2; S3, session 3; PEG, Pain, Enjoyment of Life, and General Activity Scale; VAS, visual analog scale.  
 Note. Group was coded as 0 = light weighted blanket, 1 = heavy weighted blanket.  
 Pain/anxiety/sleep diff. = difference scores (post – pre), where more negative values indicate greater reductions. More positive values indicate greater sleep quality improvements.  
 Deep : light = ratio of the amount of time in deep relative to light sleep. Values greater than 1 indicate more time spent in deep relative to light sleep.  
 95% confidence intervals for indirect effects were computed based on samples bootstrapped 5000 times.  
 Covariates = trait anxiety and session 2 expectations.  
 \*n = 93,  
 \*\*n = 87,  
 †n = 87,  
 ‡n = 66,  
 §n = 87,  
 ||n = 87,  
 ¶n = 66.

## 12 The Journal of Pain

duration conditions. The non-significant effect of weighted blankets on anxiety and sleep is surprising because previous studies have shown that weighted blankets reduce anxiety<sup>22,24,41,65,110,155</sup> and insomnia,<sup>2,41</sup> and suggests other mechanisms for the pain-relieving effect. The classic neurophysiological explanation for touch-induced analgesia is gate control theory, which posits that activation of large myelinated fibers by cutaneous stimulation inhibits ascending nociception at the level of the spinal cord.<sup>43,77,99,160</sup> Recently, A-beta stimulation was found to inhibit laser pain in the same dermatome at the level of the spinal cord, providing evidence for this theory.<sup>149</sup> We recently demonstrated that deep pressure sensation is conveyed by A-beta afferents,<sup>19</sup> suggesting that deep pressure might reduce pain through this mechanism. Peripheral effects of deep pressure, including increases in blood flow<sup>104</sup> and local tissue oxygenation<sup>6,101</sup> could also contribute to the antinociceptive effects of weighted blankets.

In the current study, however, deeper pressure reduced broader, more social and/or affective perceptions of chronic pain (ie, PEG ratings). The overall effect size we observed is similar to that seen with other commonly used non drug interventions for chronic pain such as spinal manipulation and exercise.<sup>80</sup> This is intriguing because our study was conducted during a period of elevated social isolation and psychological distress (COVID-19 pandemic).<sup>9,83</sup> Various mammalian species engage in deep body-to-body pressure for thermal regulation<sup>62</sup> and take comfort in firm pressure in the absence of others.<sup>68</sup> In humans, moderate pressure massage provided by mothers to their preterm infants is effective at alleviating depression and anxiety in both members of the dyad.<sup>44,48</sup> We speculate that deeper pressure sensations may be wired, in part, to communicate close bodily contact with conspecifics, imparting a sense of physical and psychological safety that could inhibit pain-related fear responses. Fear of pain is thought to develop when pain sensations are appraised as threatening, triggering hypervigilance and avoidance behaviors,<sup>157</sup> and ultimately, increasing chronic pain intensity and disability.<sup>95</sup> Similarly, individuals exhibiting hyperarousal from posttraumatic stress disorder demonstrate hyperalgesia and increased temporal summation of pain.<sup>103</sup> The pleasant and calming effects of deep pressure may thus reduce hyperarousal,<sup>5,20,90,159</sup> reducing affective aspects of chronic pain.

In line with a fear of pain account, we found that deeper pressure was more effective for individuals high in trait anxiety. Previous research has revealed benefits of deep body compression<sup>85</sup> and interoceptive exposure<sup>55</sup> in highly anxious individuals, potentially related to greater negative appraisals of pain and bodily sensations in such individuals.<sup>93</sup> "Interoceptive exposures" that expose patients to bodily sensations in order to decondition the associated fear reduce anxiety sensitivity<sup>16</sup> and pain-related distress,<sup>56</sup> as well as increase pain acceptance.<sup>56</sup> Learned safety – whereby a conditioned stimulus is unpaired from an aversive unconditioned

An RCT of weighted blankets for chronic pain

stimulus, becoming a predictor of safety – reduces conditioned fear responses<sup>38,84,128,133</sup> and facilitates anxiolytic, exploratory behaviors.<sup>128</sup> Similarly, positive emotions are associated with approach-orientated behaviors, resilient stress responses,<sup>12,61,134</sup> and analgesia.<sup>54,118,152,154</sup> It is possible that deep pressure sensation may constitute an interoceptive exposure that deconditions fear of pain and promotes approach behaviors that reduce the burden of chronic pain over time.

The role of the insula in affective processes offers insight into the neural mechanisms that might underpin the hypothesized safety signaling of deep pressure. We recently showed that deep pressure activates the mid-insula, slight anterior to representations of CT touch.<sup>20</sup> In rodents, the insula underlies the buffering effects of safety on stress and anxiety behaviors.<sup>26,27</sup> The insula is strongly interconnected with the amygdala,<sup>96,102,109</sup> a limbic hub critically involved in fear and threat processing, as well as heightened pain perception.<sup>7,74,121,126,163</sup> The insula<sup>102,109</sup> and amygdala<sup>96</sup> are also well connected with the striatum (putamen; caudate), a neural substrate involved in positive mood<sup>15,66,88,114,136,139</sup> and the top-down regulation of pain.<sup>154,164</sup> In humans, safety conditioning reduces activity in the amygdala and increases activity in the left caudate and prefrontal cortex,<sup>123</sup> indicative of executive-level control of fear and stress responses. Thus, activation of the insula by deep pressure is well situated to modulate limbic activity to downregulate threat, generating calm and safety. However, future psychological and neuroimaging research is required to test the effects of deep pressure on the proposed associations with fear of pain, anxiety sensitivity, and interoception.

The insula is also widely accepted to support interoception,<sup>29,30,81</sup> raising the possibility that amplification of interoceptive input in the insula may be a mechanism by which deep pressure alleviates, or deconditions, chronic pain. Massage therapy, which incorporates pressure, has been described as facilitating body awareness.<sup>90</sup> Further, osteopathic manipulation<sup>40</sup> and gentle touch therapies improve interoceptive accuracy.<sup>21</sup> Individuals with chronic pain exhibit a reduced capacity to accurately detect their internal bodily sensations,<sup>14,34,35,37,57,132</sup> and interoceptive awareness is inversely associated with chronic pain.<sup>34,37,135</sup> Interoceptive interventions have successfully reduced symptom severity in patients with somatoform disorders,<sup>131</sup> a population similarly susceptible to interoceptive deficits.<sup>35</sup> Whether such an interoceptive mechanism would require conscious attention to interoceptive sensations – or the conscious noticing and savoring of pleasant sensations in particular<sup>60</sup> – remains an open question.

Finally, the affective – and putatively social – effects of deep pressure may also operate in an ascending manner through the broad central release of oxytocin, a neuropeptide with pro-social, anxiolytic, and analgesic effects.<sup>115</sup> Oxytocin reduces chronic pain perception<sup>165</sup> and is released from tactile stimulation in rats,<sup>3</sup> and from moderate pressure massage in humans<sup>106</sup>. The



behavioral effects of oxytocin are thought to stem from centrally projecting neurons in the paraventricular nuclei (PVN) and supraoptic nuclei of the hypothalamus.<sup>13</sup> In rats, gentle stroking stimulates hypothalamic oxytocin neurons<sup>115</sup>, and light pressure and touch induce oxytocin release that acts directly in the amygdala and hypothalamus, with indirect effects on the hypothalamic-pituitary-adrenal axis,<sup>147</sup> mediating fear and stress responses.<sup>130</sup> A spinohypothalamic projection pathway was recently identified in rodents and primates that may play a role in autonomic and emotional responses to nociceptive stimuli.<sup>78,169</sup> Given that projections for affective touch have been identified in the spinoparabrachial pathway,<sup>25</sup> it is plausible that similar spinohypothalamic projections might convey affective components of deep pressure sensation to the hypothalamus, stimulating release of oxytocin. From the PVN, oxytocinergic neurons project to the rostral agranular (anterior) insula. Indeed, oxytocin enhances social approach behaviors in rodents by suppressing activity in the anterior insula,<sup>166</sup> a region extensively interconnected with affective brain regions and brainstem areas involved in descending pain inhibitory control.<sup>75, 59</sup> However, the hypothesized role of oxytocin in supporting the social and/or affective effects of deeper pressure requires further investigation.

Our exploratory analyses revealed that PEG reductions produced by the heavy weighted blanket relative to the light weighted blanket were largest in patients with chronic primary pain, which included fibromyalgia, back pain, and migraine. In contrast, pain intensity reductions were largest in the heavy weighted blanket group in patients with musculoskeletal pain, including arthritis, Ehlers Danlos Syndrome, and degenerative disc disease. This is surprising given that pressure pain thresholds are significantly lower in musculoskeletal patients,<sup>18,87</sup> which may be attributed to greater sleep disturbance in this population.<sup>87</sup> It would be interesting to determine whether this effect would increase or decrease with an even heavier weighted blanket. Although these differences comprise promising avenues for future research, they should be regarded as highly tentative because numerous participants had chronic pain diagnoses that were classified into multiple categories.

### Study Limitations

Findings from the current study should be interpreted in light of several limitations. First, the control condition in the current study was a 5-lb (2.3 kg) blanket, which distributed some pressure to the body. It is possible that our inability to detect a significant overall effect of weighted blankets on several of our outcome measurements could be because of active effects of this light blanket. Second, debriefing revealed incomplete masking of participants

due to the physical nature of the weighted blanket. Future research employing a no-treatment or waitlist control group is needed to confirm the relative effects of deeper and light pressure on pain, anxiety, and sleep in various chronic pain conditions. Third, assessment of sleep quality by a single-item VAS has not been validated, which may have limited our ability to detect an effect of the weighted blanket on sleep. Fourth, due to the brief nature of the PEG, it is difficult to fully understand the relative contributions of blanket pressure on pain intensity and interference, which both appear to contribute to the overall PEG effect. PEG results are additionally limited because we did not measure whether participants continued to wear their blankets until the completion of session 3 assessments. However, the mean number of days from the end of the weeklong trial to session 3 completion was very low ( $M < 2$ ) and did not significantly influence the results. Fifth, we employed two exclusion criteria based on reported levels of chronic pain at baseline and blanket adherence. Yet, intention-to-treat analyses are generally recommended in randomized controlled trials<sup>42</sup> and should be employed in future research. Finally, participants' chronic pain diagnoses were based on self-report, and were not confirmed by medical providers. However, participants had registered their diagnosis before being contacted about the study, and we excluded participants with PEG scores below a clinical cutoff value.

In sum, we demonstrate that a deeper pressure weighted blanket reduces aspects of chronic pain and pain interference, relative to a light pressure weighted blanket. We also provide evidence for an individual difference factor – trait anxiety – in elucidating who might benefit the most from deeper pressure. These findings are promising given the low-cost and accessibility of this intervention, as well as its excellent safety profile.<sup>22,110</sup> Further research is required to determine whether effects of the weighted blanket extend beyond the period of use. In addition, research is required to determine whether conscious attention or positive reappraisal of bodily sensations are operational mechanisms supporting the benefits of deep pressure, and for which chronic pain conditions the blanket may be most effective. Overall, we show that deeper pressure sensations can be leveraged to reduce the burden of chronic pain, offering a low-cost and easy-to-use tool for individuals with chronic pain, especially those high in trait anxiety.

### Acknowledgments

Weighted blankets were purchased from SensaCalm. We would like to thank Dr. Christina Wierenga for sharing access to the LifeData System.

### References

1. Abend R, Dan O, Maoz K, Raz S, Bar Haim Y: Reliability, validity and sensitivity of a computerized visual analog scale measuring state anxiety. *J Behav Ther Exp Psychiatry* 45:447-453, 2014
2. Ackerley R, Badre G, Olausson H: Positive effects of a weighted blanket on insomnia. *J Sleep Med Disord* 2:1-7, 2015
3. Agren G, Lundeberg T, Uvnäs Moberg K, Sato A: The oxytocin antagonist 1-deamino-2-D-Tyr-(Oet)-4-Thr-8-Orn-oxytocin reverses the increase in the withdrawal response

## 14 The Journal of Pain

latency to thermal, but not mechanical nociceptive stimuli following oxytocin administration or massage-like stroking in rats. *Neurosci Lett* 187:49-52, 1995

4. al Absi M, Rokke PD: Can anxiety help us tolerate pain? *Pain* 46:43-51, 1991

5. Ali A, Rosenberger L, Weiss TR, Milak C, Perlman AI: Massage therapy and quality of life in osteoarthritis of the knee: A qualitative study. *Pain Med* 18:1168-1175, 2017

6. Altindag O, Celik H: Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. *Redox Rep Commun Free Radical Res* 11:131-135, 2006

7. Amaral DG: The amygdala, social behavior, and danger detection. *Ann NY Acad Sci* 1000:337-347, 2003

8. Anamkath NS, Palyo SA, Jacobs SC, Lartigue A, Schopmeyer K, Strigo IA: An Interdisciplinary Pain Rehabilitation Program for Veterans with chronic pain: Description and initial evaluation of outcomes. *Pain Res Manage* 2018:3941682, 2018

9. Asquini G, Bianchi AE, Borromeo G, Locatelli M, Falla D: The impact of Covid-19-related distress on general health, oral behavior, psychosocial features, disability and pain intensity in a cohort of Italian patients with temporomandibular disorders. *PLoS One* 16:e0245999, 2021

10. Baliki MN, Chialvo DR, Geha PY, Levy RM, Harden RN, Parrish TB, Apkarian AV: Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. *J Neurosci* 26:12165-12173, 2006

11. Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, Fields HL, Apkarian AV: Corticostriatal functional connectivity predicts transition to chronic back pain. *Nat Neurosci* 15:1117-1119, 2012

12. Baumgartner JN, Schneider TR, Capiola A: Investigating the relationship between optimism and stress responses: A biopsychosocial perspective. *Pers Individ Dif* 129:114-118, 2018

13. Bethlehem RA, van Honk J, Auyeung B, Baron Cohen S: Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies. *Psychoneuroendocrinology* 38:962-974, 2013

14. Blanchard EB, Jurish SE, Andrasik F, Epstein LH: The relationship between muscle discrimination ability and response to relaxation training in three kinds of headaches. *Biofeedback Self Regul* 6:537-545, 1981

15. Blood AJ, Zatorre RJ: Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. *Proc Natl Acad Sci USA* 98:11818-11823, 2001

16. Boswell JF, Farchione TJ, Sauer Zavala S, Murray HW, Fortune MR, Barlow DH: Anxiety sensitivity and interoceptive exposure: A transdiagnostic construct and change strategy. *Behav Ther* 44:417-431, 2013

17. Bushnell MC, Čeko M, Low LA: Cognitive and emotional control of pain and its disruption in chronic pain. *Nat Rev Neurosci* 14:502-511, 2013

18. Carlesso LC, Segal NA, Frey-Law L, Zhang Y, Na L, Nevitt M, Lewis CE, Neogi T: Pain susceptibility phenotypes in those free of knee pain with or at risk of knee

An RCT of weighted blankets for chronic pain

osteoarthritis: The multicenter osteoarthritis study. *Arthritis Rheumatol* 71:542-549, 2019

19. Case LK, Liljencrantz J, Madian N, Necaie A, Tubbs J, McCall M, Bradson ML, Szczot M, Pitcher MH, Ghitani N, Frangos E, Cole J, Bharucha Goebel D, Saade D, Ogata T, Donkervoort S, Foley AR, Bönnemann CG, Olausson H, Bushnell MC, Chesler AT: Innocuous pressure sensation requires A-type afferents but not functional PIEZO2 channels in humans. *Nat Commun* 12:657, 2021

20. Case LK, Liljencrantz J, McCall MV, Bradson M, Necaie A, Tubbs J, Olausson H, Wang B, Bushnell MC: Pleasant deep pressure: Expanding the social touch hypothesis. *Neuroscience* 464:3-11, 2020

21. Cerritelli F, Chiacchiaretta P, Gambi F, Perrucci MG, Barassi G, Visciano C, Bellomo RG, Saggini R, Ferretti A: Effect of manual approaches with osteopathic modality on brain correlates of interoception: An fMRI study. *Sci Rep* 10:3214, 2020

22. Champagne T, Mullen B, Dickson D, Krishnamurty S: Evaluating the safety and effectiveness of the weighted blanket with adults during an inpatient mental health hospitalization. *Occup Ther Mental Health* 31:211-233, 2015

23. Champagne T, Stromberg N: Sensory approaches in inpatient psychiatric settings: innovative alternatives to seclusion & restraint. *J Psychosoc Nurs Ment Health Serv* 42:34-44, 2004

24. Chen H-Y, Yang H, Chi H-J, Chen H-M: Physiological effects of deep touch pressure on anxiety alleviation: The weighted blanket approach. *J Med Biol Eng* 33:463-470, 2013

25. Choi S, Hachisuka J, Brett MA, Magee AR, Omori Y, Zhang D, DeLisle MM, Wolfson RL, Bai L, Santiago C: Parallel ascending spinal pathways for affective touch and pain. *Nature* 587:258-263, 2020

26. Christianson JP, Benison AM, Jennings J, Sandsmark EK, Amat J, Kaufman RD, Baratta MV, Paul ED, Campeau S, Watkins LR, Barth DS, Maier SF: The sensory insular cortex mediates the stress-buffering effects of safety signals but not behavioral control. *J Neurosci* 28:13703-13711, 2008

27. Christianson JP, Jennings JH, Ragole T, Flyer JG, Benison AM, Barth DS, Watkins LR, Maier SF: Safety signals mitigate the consequences of uncontrollable stress via a circuit involving the sensory insular cortex and bed nucleus of the stria terminalis. *Biol Psychiatry* 70:458-464, 2011

28. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. *Ann Acad Med Singap* 23:129-138, 1994

29. Craig AD: Interoception: the sense of the physiological condition of the body. *Curr Opin Neurobiol* 13:500-505, 2003

30. Craig AD: How do you feel—now? The anterior insula and human awareness. *Nat Rev Neurosci* 10:59-70, 2009

31. Curtin F, Schulz P: Multiple correlations and Bonferroni's correction. *Biol Psychiatry* 44:775-777, 1998

32. Davis KD, Moayedi M: Central mechanisms of pain revealed through functional and structural MRI. *J Neuroimmune Pharmacol* 8:518-534, 2013

33. Depp CA, Moore RC, Dev SI, Mausbach BT, Eyer LT, Granholm EL: The temporal course and clinical correlates of subjective impulsivity in bipolar disorder as revealed through ecological momentary assessment. *J Affect Disord* 193:145-150, 2016
34. Di Lernia D, Lacerenza M, Ainley V, Riva G: Altered interoceptive perception and the effects of interoceptive analgesia in musculoskeletal, primary, and neuropathic chronic pain conditions. *J Personalized Med* 10:201, 2020
35. Di Lernia D, Serino S, Riva G: Pain in the body. Altered interoception in chronic pain conditions: A systematic review. *Neurosci Biobehav Rev* 71:328-341, 2016
36. Diego MA, Field T, Sanders C, Hernandez Reif M: Massage therapy of moderate and light pressure and vibrator effects on EEG and heart rate. *Int J Neurosci* 114:31-44, 2004
37. Duschek S, Montoro CI, Reyes Del Paso GA: Diminished interoceptive awareness in fibromyalgia syndrome. *Behav Med* 43:100-107, 2017
38. Eckstein M, Mamaev I, Ditzen B, Sailer U: Calming effects of touch in human, animal, and robotic interaction—scientific state-of-the-art and technical advances. *Front Psychiatry* 11:555058, 2020
39. Edelson SM, Edelson MG, Kerr DC, Grandin T: Behavioral and physiological effects of deep pressure on children with autism: a pilot study evaluating the efficacy of Grandin's Hug Machine. *Am J Occup Ther* 53:145-152, 1999
40. Edwards DJ, Young H, Cutis A, Johnston R: The immediate effect of therapeutic touch and deep touch pressure on range of motion, interoceptive accuracy and heart rate variability: A randomized controlled trial with moderation analysis. *Front Integr Neurosci* 12:41, 2018
41. Ekholm B, Spulber S, Adler M: A randomized controlled study of weighted chain blankets for insomnia in psychiatric disorders. *J Clin Sleep Med* 16:1567-1577, 2020
42. Elkins MR, Moseley AM: Intention-to-treat analysis. *J Physiother*. 61:165-167, 2015
43. Ellrich J, Lamp S: Peripheral nerve stimulation inhibits nociceptive processing: an electrophysiological study in healthy volunteers. *Neuromodulation* 8:225-232, 2005
44. Feijó L, Hernandez Reif M, Field T, Burns W, Valley-Gray S, Simco E: Mothers' depressed mood and anxiety levels are reduced after massaging their preterm infants. *Infant Behav Dev* 29:476-480, 2006
45. Fidanza F, Polimeni E, Pierangeli V, Martini M: A better touch: C-tactile fibres related activity is associated to pain reduction during temporal summation of second pain. *J Pain* 22:567-576, 2021
46. Field T, Diego M, Cullen C, Hernandez Reif M, Sunshine W, Douglas S: Fibromyalgia pain and substance P decrease and sleep improves after massage therapy. *J Clin Rheumatol* 8:72-76, 2002
47. Field T, Diego M, Hernandez Reif M: Moderate pressure is essential for massage therapy effects. *Int J Neurosci* 120:381-385, 2010
48. Field T, Diego M, Hernandez Reif M: Preterm infant massage therapy research: A review. *Infant Behav Dev* 33:115-124, 2010
49. Field T, Diego MA, Hernandez Reif M, Schanberg S, Kuhn C: Massage therapy effects on depressed pregnant women. *J Psychosom Obstet Gynaecol* 25:115-122, 2004
50. Field T, Figueiredo B, Hernandez Reif M, Diego M, Deeds O, Ascencio A: Massage therapy reduces pain in pregnant women, alleviates prenatal depression in both parents and improves their relationships. *J Bodywork Mov Ther* 12:146-150, 2008
51. Field T, Hernandez Reif M, Diego M, Schanberg S, Kuhn C: Cortisol decreases and serotonin and dopamine increase following massage therapy. *Int J Neurosci* 115:1397-1413, 2005
52. Field T, Hernandez Reif M, Hart S, Theakston H, Schanberg S, Kuhn C: Pregnant women benefit from massage therapy. *J Psychosom Obstet Gynaecol* 20:31-38, 1999
53. Field T, Hernandez Reif M, Taylor S, Quintino O, Burman I: Labor pain is reduced by massage therapy. *J Psychosom Obstet Gynaecol* 18:286-291, 1997
54. Finan PH, Garland EL: The role of positive affect in pain and its treatment. *Clin J Pain* 31:177-187, 2015
55. Flack F, Stahlschmidt L, Dobe M, Hirschfeld G, Strasser A, Michalak J, Wager J, Zernikow B: Efficacy of adding interoceptive exposure to intensive interdisciplinary treatment for adolescents with chronic pain: a randomized controlled trial. *Pain* 159:2223-2233, 2018
56. Flink IK, Nicholas MK, Boersma K, Linton SJ: Reducing the threat value of chronic pain: A preliminary replicated single-case study of interoceptive exposure versus distraction in six individuals with chronic back pain. *Behav Res Ther* 47:721-728, 2009
57. Flor H, Schugens MM, Birbaumer N: Discrimination of muscle tension in chronic pain patients and healthy controls. *Biofeedback Self Regul* 17:165-177, 1992
58. Frey Law LA, Evans S, Knudtson J, Nus S, Scholl K, Sluka KA: Massage reduces pain perception and hyperalgesia in experimental muscle pain: a randomized, controlled trial. *J Pain* 9:714-721, 2008
59. Gamal Eltrabily M, de Los Monteros Zúñiga AE, Manzano García A, Martínez Lorenzana G, Condés Lara M, González Hernández A: The rostral agranular insular cortex, a new site of oxytocin to induce antinociception. *J Neurosci* 40:5669-5680, 2020
60. Garland EL: Psychosocial intervention and the reward system in pain and opioid misuse: New opportunities and directions. *Pain* 161:2659-2666, 2020
61. Garland EL, Geschwind N, Peeters F, Wichers M: Mindfulness training promotes upward spirals of positive affect and cognition: multilevel and autoregressive latent trajectory modeling analyses. *Front Psychol* 6:15, 2015
62. Gilbert C, McCafferty D, Le Maho Y, Martrette JM, Giroud S, Blanc S, Ancel A: One for all and all for one: the energetic benefits of huddling in endotherms. *Biol Rev Camb Philos Soc* 85:545-569, 2010
63. Gordon I, Voos AC, Bennett RH, Bolling DZ, Pelphrey KA, Kaiser MD: Brain mechanisms for processing affective touch. *Hum Brain Mapp* 34:914-922, 2013
64. Grandin T: Calming effects of deep touch pressure in patients with autistic disorder, college students, and animals. *J Child Adolesc Psychopharmacol* 2:63-72, 1992

## 16 The Journal of Pain

65. Gringras P, Green D, Wright B, Rush C, Sparrowhawk M, Pratt K, Allgar V, Hooke N, Moore D, Zaiwalla Z, Wiggs L: Weighted blankets and sleep in autistic children—a randomized controlled trial. *Pediatrics* 134:298-306, 2014
66. Grosse Rueschkamp JM, Brose A, Villringer A, Gaebler M: Neural correlates of up-regulating positive emotions in fMRI and their link to affect in daily life. *Soc Cogn Affect Neurosci* 14:1049-1059, 2019
67. Habig K, Schänzer A, Schirner W, Lautenschläger G, Dassinger B, Olausson H, Birklein F, Gizewski ER, Krämer HH: Low threshold unmyelinated mechanoafferents can modulate pain. *BMC Neurol* 17:184, 2017
68. Harlow HF: Love in infant monkeys. *Sci. Am.* 200:68-75, 1959
69. Hayes AF: Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. Guilford Publications, 2017
70. Hayes AF, Rockwood NJ: Regression-based statistical mediation and moderation analysis in clinical research: Observations, recommendations, and implementation. *Behav Res Ther* 98:39-57, 2017
71. Hernandez Reif M, Field T, Krasnegor J, Theakston H: Lower back pain is reduced and range of motion increased after massage therapy. *Int J Neurosci* 106:131-145, 2001
72. Honigman L, Bar-Bachar O, Yarnitsky D, Sprecher E, Granovsky Y: Nonpainful wide-area compression inhibits experimental pain. *Pain* 157:2000-2011, 2016
73. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd Allah F, Abdela J, Abdelalim A: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* 392:1789-1858, 2018
74. Janak PH, Tye KM: From circuits to behavior in the amygdala. *Nature* 517:284-292, 2015
75. Jasmin L, Granato A, Ohara PT: Rostral agranular insular cortex and pain areas of the central nervous system: A tract-tracing study in the rat. *J Comp Neurol* 468:425-440, 2004
76. Kain ZN, Sevarino F, Alexander GM, Pincus S, Mayes LC: Preoperative anxiety and postoperative pain in women undergoing hysterectomy. A repeated-measures design. *J Psychosom Res* 49:417-422, 2000
77. Kakigi R, Shibasaki H: Mechanisms of pain relief by vibration and movement. *J Neurol Neurosurg Psychiatry* 55:282-286, 1992
78. Katter JT, Dado RJ, Kostarczyk E, Giesler GJ: Spinothalamic and spinothalamic tract neurons in the sacral spinal cord of rats. II. Responses to cutaneous and visceral stimuli. *J Neurophysiol* 75:2606-2628, 1996
79. Kaufmann CN, Gershon A, Eyler LT, Depp CA: Clinical significance of mobile health assessed sleep duration and variability in bipolar disorder. *J Psychiatr Res* 81:152-159, 2016
80. Keller A, Hayden J, Bombardier C, Van Tulder M: Effect sizes of non-surgical treatments of non-specific low-back pain. *Eur Spine J* 16:1776-1788, 2007
81. Khalsa SS, Rudrauf D, Feinstein JS, Tranel D: The pathways of interoceptive awareness. *Nat Neurosci* 12:1494-1496, 2009
82. Kirsch LP, Besharati S, Papadaki C, Crucianelli L, Bertagnoli S, Ward N, Moro V, Jenkinson PM, Fotopoulou A: Damage to the right insula disrupts the perception of affective touch. *eLife* 9:e47895, 2020
83. Kleinmann B, Abberger B, Kieselbach K, Wolter T: Patients with chronic pain prefer maintenance of pain treatment despite COVID-19 pandemic restrictions. *Pain Physician* 24:165-173, 2021
84. Kong E, Monje FJ, Hirsch J, Pollak DD: Learning not to fear: neural correlates of learned safety. *Neuropsychopharmacology* 39:515-527, 2014
85. Krauss KE: The effects of deep pressure touch on anxiety. *Am J Occup Ther* 41:366-373, 1987
86. Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, Asch SM, Kroenke K: Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med* 24:733-738, 2009
87. Lee YC, Lu B, Edwards RR, Wasan AD, Nassikas NJ, Clauw DJ, Solomon DH, Karlson EW: The role of sleep problems in central pain processing in rheumatoid arthritis. *Arthritis Rheum* 65:59-68, 2013
88. Li F, Yin S, Feng P, Hu N, Ding C, Chen A: The cognitive up- and down-regulation of positive emotion: Evidence from behavior, electrophysiology, and neuroimaging. *Biol Psychol* 136:57-66, 2018
89. Liljencrantz J, Strigo I, Ellingsen DM, Krämer HH, Lundblad LC, Nagi SS, Leknes S, Olausson H: Slow brushing reduces heat pain in humans. *Eur J Pain (London, England)* 21:1173-1185, 2017
90. Lindgren L, Jacobsson M, Lämås K: Touch massage, a rewarding experience. *J Holist Nurs* 32:261-268, 2014
91. Loken LS, Evert M, Wessberg J: Pleasantness of touch in human glabrous and hairy skin: order effects on affective ratings. *Brain Res* 1417:9-15, 2011
92. Loken LS, Wessberg J, Morrison I, McGlone F, Olausson H: Coding of pleasant touch by unmyelinated afferents in humans. *Nat Neurosci* 12:547-548, 2009
93. Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan Ludewig K: Information-processing deficits and cognitive dysfunction in panic disorder. *J Psychiatry Neurosci* 30:37-43, 2005
94. Mahns DA, Nagi SS: An investigation into the peripheral substrates involved in the tactile modulation of cutaneous pain with emphasis on the C-tactile fibres. *Exp. Brain Res* 227:457-465, 2013
95. Martinez Calderon J, Flores Cortes M, Morales Asencio JM, Luque Suarez A: Pain-related fear, pain intensity and function in individuals with chronic musculoskeletal pain: A systematic review and meta-analysis. *J. Pain.* 20:1394-1415, 2019
96. McDonald AJ, Shammah Lagnado SJ, Shi C, Davis M: Cortical afferents to the extended amygdala. *Ann NY Acad Sci* 877:309-338, 1999
97. McGlone F, Vallbo AB, Olausson H, Loken L, Wessberg J: Discriminative touch and emotional touch. *Can J Exp Psychol* 61:173-183, 2007



98. McGlone F, Wessberg J, Olausson H: Discriminative and affective touch: sensing and feeling. *Neuron* 82:737-755, 2014
99. Melzack R, Wall PD: Pain mechanisms: A new theory. *Science* 150:971-979, 1965
100. Merlin JS, Westfall AO, Long D, Davies S, Saag M, Demonte W, Young S, Kerns RD, Bair MJ, Kertesz S, Turan JM, Kilgore M, Clay OJ, Starrels J, Pekmezi D, MO Johnson: A Randomized Pilot Trial of a novel behavioral intervention for chronic pain tailored to individuals with HIV. *AIDS Behav* 22:2733-2742, 2018
101. Messere A, Ceravolo G, Franco W, Maffiodo D, Ferraresi C, Roatta S: Increased tissue oxygenation explains the attenuation of hyperemia upon repetitive pneumatic compression of the lower leg. *J Appl Physiol* 123:1451-1460, 2017
102. Mesulam MM, Mufson EJ: Insula of the old world monkey. III: Efferent cortical output and comments on function. *J Comp Neurol* 212:38-52, 1982
103. Moeller-Bertram T, Strigo IA, Simmons AN, Schilling JM, Patel P, Baker DG: Evidence for acute central sensitization to prolonged experimental pain in posttraumatic stress disorder. *Pain Med* 15:762-771, 2014
104. Monteiro Rodrigues L, Rocha C, Ferreira HT, Silva HN: Lower limb massage in humans increases local perfusion and impacts systemic hemodynamics. *J Appl Physiol* 128:1217-1226, 2020
105. Moore RC, Kaufmann CN, Rooney AS, Moore DJ, Eyler LT, Granholm E, Woods SP, Swendsen J, Heaton RK, Scott JC, Depp CA: Feasibility and acceptability of ecological momentary assessment of daily functioning among older adults with HIV. *Am J Geriatr Psychiatry* 25:829-840, 2017
106. Morhenn V, Beavin LE, Zak PJ: Massage increases oxytocin and reduces adrenocorticotropin hormone in humans. *Altern Ther Health Med* 18:11, 2012
107. Morley S: Efficacy and effectiveness of cognitive behaviour therapy for chronic pain: progress and some challenges. *Pain* 152:599-5106, 2011
108. Morrison I, Loken LS, Olausson H: The skin as a social organ. *Exp Brain Res* 204:305-314, 2010
109. Mufson EJ, Mesulam MM: Insula of the old world monkey. II: Afferent cortical input and comments on the claustrum. *J Comp Neurol* 212:23-37, 1982
110. Mullen B, Champagne T, Krishnamurty S, Dickson D, Gao R: Exploring the safety and therapeutic effects of deep pressure stimulation using a weighted blanket. *Occup Ther Mental Health* 24:65-89, 2008
111. Nagi SS, Macefield VG, Mahns DA: Modulatory role of C-tactile fibres in overt and covert muscle pain. *Neurosci Res* 71, 2011. e80-e80
112. Nascimento SS, Oliveira LR, DeSantana JM: Correlations between brain changes and pain management after cognitive and meditative therapies: a systematic review of neuroimaging studies. *Complement Ther Med* 39:137-145, 2018
113. Nelson LS, Juurlink DN, Perrone J: Addressing the opioid epidemic. *JAMA* 314:1453-1454, 2015
114. Nikolova YS, Bogdan R, Brigidi BD, Hariri AR: Ventral striatum reactivity to reward and recent life stress interact to predict positive affect. *Biol Psychiatry* 72:157-163, 2012
115. Okabe S, Yoshida M, Takayanagi Y, Onaka T: Activation of hypothalamic oxytocin neurons following tactile stimuli in rats. *Neurosci Lett* 600:22-27, 2015
116. Olausson H, Cole J, Rylander K, McGlone F, Lamarre Y, Wallin BG, Kramer H, Wessberg J, Elam M, Bushnell MC, Vallbo A: Functional role of unmyelinated tactile afferents in human hairy skin: sympathetic response and perceptual localization. *Exp Brain Res* 184:135-140, 2008
117. Olausson H, Wessberg J, Morrison I, McGlone F, Vallbo A: The neurophysiology of unmyelinated tactile afferents. *Neurosci Biobehav Rev* 34:185-191, 2010
118. Ong AD, Thoemmes F, Ratner K, Ghezzi-Kopel K, MC Reid: Positive affect and chronic pain: a preregistered systematic review and meta-analysis. *Pain* 161:1140-1149, 2020
119. Pawling R, Cannon PR, McGlone FP, Walker SC: C-tactile afferent stimulating touch carries a positive affective value. *PLoS One* 12:e0173457, 2017
120. Pawling R, Trotter PD, McGlone FP, Walker SC: A positive touch: C-tactile afferent targeted skin stimulation carries an appetitive motivational value. *Biol Psychol* 129:186-194, 2017
121. Phelps EA, LeDoux JE: Contributions of the amygdala to emotion processing: from animal models to human behavior. *Neuron* 48:175-187, 2005
122. Ploghaus A, Narain C, Beckmann C, Wise R, Bantick S, Clare S, Rawlins N, Tracey I: Anxiety increases perceived pain intensity: A hippocampal mechanism. *NeuroImage* 13: S462, 2001
123. Pollak DD, Rogan MT, Eegner T, Perez DL, Yanagihara TK, Hirsch J: A translational bridge between mouse and human models of learned safety. *Ann Med* 42:115-122, 2010
124. Preacher KJ, Hayes AF: SPSS and SAS procedures for estimating indirect effects in simple mediation models. *Behav Res Methods Instrum Comput* 36:717-731, 2004
125. Price DD, McGrath PA, Rafii A, Buckingham B: The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. *Pain* 17:45-56, 1983
126. Reicherts P, Wiemer J, Gerdes ABM, Schulz SM, Pauli P, Wieser MJ: Anxious anticipation and pain: the influence of instructed vs conditioned threat on pain. *Soc Cogn Affect Neurosci* 12:544-554, 2017
127. Rhudy JL, Meagher MW: Fear and anxiety: divergent effects on human pain thresholds. *Pain* 84:65-75, 2000
128. Rogan MT, Leon KS, Perez DL, Kandel ER: Distinct neural signatures for safety and danger in the amygdala and striatum of the mouse. *Neuron* 46:309-320, 2005
129. Rolls ET, O'Doherty J, Kringelbach ML, Francis S, Bowtell R, McGlone F: Representations of pleasant and painful touch in the human orbitofrontal and cingulate cortices. *Cerebral cortex* 13:308-317, 2003
130. Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating

**18 The Journal of Pain**

permissive, suppressive, stimulatory, and preparative actions. *Endocr. Rev.* 21:55-89, 2000

131. Schaefer M, Egloff B, Gerlach AL, Witthöft M: Improving heartbeat perception in patients with medically unexplained symptoms reduces symptom distress. *Biol. Psychol.* 101:69-76, 2014

132. Schandry R: Heart beat perception and emotional experience. *Psychophysiology* 18:483-488, 1981

133. Schiller D, Levy I, Niv Y, LeDoux JE, Phelps EA: From fear to safety and back: reversal of fear in the human brain. *J Neurosci* 28:11517-11525, 2008

134. Schneider TR: The role of neuroticism on psychological and physiological stress responses. *J Exp Soc Psychol* 40:795-804, 2004

135. Schroeder S, Gerlach AL, Achenbach S, Martin A: The relevance of accuracy of heartbeat perception in noncardiac and cardiac chest pain. *Int. J. Behav. Med.* 22:258-267, 2015

136. Schultz W, Apicella P, Scarnati E, Ljungberg T: Neuronal activity in monkey ventral striatum related to the expectation of reward. *J Neurosci* 12:4595-4610, 1992

137. Schweinhardt P, Bushnell MC: Pain imaging in health and disease—how far have we come? *J Clin Invest* 120:3788-3797, 2010

138. Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ: The integration of negative affect, pain and cognitive control in the cingulate cortex. *NatRev Neurosci* 12:154-167, 2011

139. Shenhav A, Buckner RL: Neural correlates of dueling affective reactions to win-win choices. *Proc Natl Acad Sci USA* 111:10978-10983, 2014

140. Sivertsen B, Lallukka T, Petrie KJ, Steingrimsdóttir Ó A, Stubhaug A, Nielsen CS: Sleep and pain sensitivity in adults. *Pain* 156:1433-1439, 2015

141. Solberg Nes L, Roach AR, Segerstrom SC: Executive functions, self-regulation, and chronic pain: a review. *Ann Behav Med* 37:173-183, 2009

142. Spielberger C: *Manual for the State-Trait Anxiety Inventory (STAI-Form Y)*. Palo Alto, CA, Consulting Psychology Press, 1983

143. Sylvia LG, Shesler LW, Peckham AD, Grandin T, Kahn DA: Adjunctive deep touch pressure for comorbid anxiety in bipolar disorder: mediated by control of sensory input? *J. Psychiatr. Pract.* 20:71-77, 2014

144. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ: Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). *Pain* 160:19-27, 2019

145. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Kosek E, Lavand'homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ: A classification of chronic pain for ICD-11. *Pain* 156:1003-1007, 2015

An RCT of weighted blankets for chronic pain

146. Turner JA, Anderson ML, Balderson BH, Cook AJ, Sherman KJ, Cherkin DC: Mindfulness-based stress reduction and cognitive-behavioral therapy for chronic low back pain: similar effects on mindfulness, catastrophizing, self-efficacy, and acceptance in a randomized controlled trial. *Pain* 157:2434, 2016

147. Uvnäs Moberg K, Handlin L, Petersson M: Self-soothing behaviors with particular reference to oxytocin release induced by non-noxious sensory stimulation. *Front Psychol* 5:1529, 2015

148. Vachon Presseau E, Centeno M, Ren W, Berger S, Tetreault P, Ghantous M, Baria A, Farmer M, Baliki M, Schnitzer T: The emotional brain as a predictor and amplifier of chronic pain. *Jo Dental Res* 95:605-612, 2016

149. Valeriani M, Pazzaglia C, Rizzo V, Quartarone A, Voltono C: Laser evoked potential amplitude and laser-pain rating reduction during high-frequency non-noxious somatosensory stimulation. *Clin Neurophysiol* 129:920-925, 2018

150. Vallbo Å, Olausson H, Wessberg J: Unmyelinated afferents constitute a second system coding tactile stimuli of the human hairy skin. *J Neurophysiol* 81:2753-2763, 1999

151. van den Hout JH, Vlaeyen JW, Houben RM, Soeters AP, Peters ML: The effects of failure feedback and pain-related fear on pain report, pain tolerance, and pain avoidance in chronic low back pain patients. *Pain* 92:247-257, 2001

152. Villemure C, Bushnell MC: Mood influences supraspinal pain processing separately from attention. *J Neurosci* 29:705-715, 2009

153. Villemure C, Ceko M, Cotton VA, Bushnell MC: Insular cortex mediates increased pain tolerance in yoga practitioners. *Cereb Cortex* 24:2732-2740, 2014

154. Villemure C, Laferriere AC, Bushnell MC: The ventral striatum is implicated in the analgesic effect of mood changes. *Pain Res Manag* 17:69-74, 2012

155. Vinson J, Powers J, Mosesso K: Weighted blankets: anxiety reduction in adult patients receiving chemotherapy. *Clin J Oncol Nurs* 24:360-368, 2020

156. Vitiello MV, Rybarczyk B, Von Korff M, Stepanski EJ: Cognitive behavioral therapy for insomnia improves sleep and decreases pain in older adults with co-morbid insomnia and osteoarthritis. *J Clin Sleep Med* 5:355-362, 2009

157. Vlaeyen JWS, Linton SJ: Fear-avoidance model of chronic musculoskeletal pain: 12 years on. *Pain* 153:1144-1147, 2012

158. Wager TD, Atlas LY, Lindquist MA, Roy M, Woo CW, Kross E: An fMRI-based neurologic signature of physical pain. *N Engl J Med* 368:1388-1397, 2013

159. Walach H, Gütthlin C, König M: Efficacy of massage therapy in chronic pain: a pragmatic randomized trial. *J Altern Complement Med* 9:837-846, 2003

160. Wall PD: Comments after 30 years of the gate control theory In: *Pain Forum*. Vol 1. Elsevier, 1996, pp 12-22

161. Watkins RH, Dione M, Ackerley R, Backlund Wasling H, Wessberg J, Löken LS: Evidence for sparse C-tactile afferent innervation of glabrous human hand skin. *J Neurophysiol* 125:232-237, 2021

162. Wells RE, O'Connell N, Pierce CR, Estave P, Penzien DB, Loder E, Zeidan F, Houle TT: Effectiveness of mindfulness meditation vs headache education for adults with migraine: A Randomized Clinical Trial. *JAMA Intern Med* 181:317-328, 2021
163. Wilson TD, Valdivia S, Khan A, Ahn HS, Adke AP, Martinez Gonzalez S, Sugimura YK, Carrasquillo Y: Dual and opposing functions of the central amygdala in the modulation of pain. *Cell Rep* 29:332-346, 2019. e335
164. Woo CW, Roy M, Buhle JT, Wager TD: Distinct brain systems mediate the effects of nociceptive input and self-regulation on pain. *PLoS Biol* 13:e1002036, 2015
165. Yang J: Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system. *Spine* 19:867-871, 1994
166. Yao S, Zhao W, Geng Y, Chen Y, Zhao Z, Ma X, Xu L, Becker B, Kendrick KM: Oxytocin facilitates approach behavior to positive social stimuli via decreasing anterior insula activity. *Int J Neuropsychopharmacol* 21:918-925, 2018
167. Zeidan F, Emerson NM, Farris SR, Ray JN, Jung Y, McHaffie JG, Coghill RC: Mindfulness meditation-based pain relief employs different neural mechanisms than placebo and sham mindfulness meditation-induced analgesia. *J Neurosci* 35:15307-15325, 2015
168. Zeidan F, Martucci KT, Kraft RA, Gordon NS, McHaffie JG, Coghill RC: Brain mechanisms supporting the modulation of pain by mindfulness meditation. *J. Neurosci* 31:5540-5548, 2011
169. Zhang X, Wenk H, Gokin A, Honda C, Giesler G: Physiological studies of spinothalamic tract neurons in the lumbar enlargement of monkeys. *J Neurophysiol* 82:1054-1058, 1999